SciSparc
SPRCSciSparc Ltd. (NASDAQ: SPRC) is a clinical-stage pharmaceutical company based in Israel. The company's primary business focus is the development of cannabinoid-based drug candidates and therapies. Its research and development efforts are concentrated on creating treatments for central nervous system disorders, utilizing proprietary technology platforms to enhance the efficacy and safety of cannabinoid compounds. The company's pipeline targets specific therapeutic areas within neuroscience. Its lead programs are aimed at conditions such as Tourette syndrome, Alzheimer's disease agitation and psychosis, and chronic pain. SciSparc's approach often involves combining cannabinoids with other approved drugs to create synergistic effects, which is a core component of its development strategy. As a publicly traded entity, the company's progress is measured through its advancement of these candidates through clinical trial phases. SciSparc's operations encompass the entire drug development continuum, from preclinical research to clinical trials. The company holds intellectual property related to its unique combinations and delivery systems. Its work is conducted in accordance with regulatory pathways, with the goal of achieving market approval for its pharmaceutical products from agencies like the U.S. Food and Drug Administration.
SPRC · Stock Price
Historical price data
About
SciSparc Ltd. (NASDAQ: SPRC) is a clinical-stage pharmaceutical company based in Israel. The company's primary business focus is the development of cannabinoid-based drug candidates and therapies. Its research and development efforts are concentrated on creating treatments for central nervous system disorders, utilizing proprietary technology platforms to enhance the efficacy and safety of cannabinoid compounds. The company's pipeline targets specific therapeutic areas within neuroscience. Its lead programs are aimed at conditions such as Tourette syndrome, Alzheimer's disease agitation and psychosis, and chronic pain. SciSparc's approach often involves combining cannabinoids with other approved drugs to create synergistic effects, which is a core component of its development strategy. As a publicly traded entity, the company's progress is measured through its advancement of these candidates through clinical trial phases. SciSparc's operations encompass the entire drug development continuum, from preclinical research to clinical trials. The company holds intellectual property related to its unique combinations and delivery systems. Its work is conducted in accordance with regulatory pathways, with the goal of achieving market approval for its pharmaceutical products from agencies like the U.S. Food and Drug Administration.